Shankar Musunuri, PhD, MBA
Dr. Musunuri is the Co-founder, Chairman and CEO of Ocugen, Inc. Dr. Musunuri is a seasoned biotech veteran with over 24 years of results-driven experience that includes advancing and commercializing a diverse portfolio of products for numerous companies ranging from “Big Pharma” to novel start-up biotechs. As a serial entrepreneur, Dr. Musunuri has raised upwards of $180 million in capital. Dr. Musunuri was the former President, Chief Executive Officer and board member of ioGenetics, Inc. Prior to ioGenetics, Dr. Musunuri was a Founder, President, Chief Executive Officer, and a board member of Nuron Biotech, Inc. Previously, Dr. Musunuri spent nearly fifteen years at Pfizer where he had held various positions of increasing leadership and responsibility. At Pfizer, his extensive experience in product launches and product life-cycle management included the most successful launch in vaccine history, Prevnar 13®, where he was played a key role as the Global Operations Team Leader. Prior to Pfizer, Dr. Musunuri worked for Amylin Pharmaceuticals. Dr. Musunuri has won numerous company, society and organizational awards.
Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy. He serves on the Advisory Board of Fuqua’s Center for Entrepreneurship and Innovation.
Daniel Jorgensen, MD, MPH, MBA
Dr. Jorgensen is an accomplished physician executive with approximately 20 years of experience in the biopharmaceutical industry, in small and large companies, including 10 years at Pfizer. He has comprehensive research, development, and commercialization experience for small molecules, biologics/vaccines, and devices, across multiple therapeutic areas, particularly infectious diseases and immunology/inflammation. Dr. Jorgensen began his industry career at Pasteur Merieux Connaught, developing vaccines for hepatitis A and rabies. While at Pfizer, he led antibiotic development teams for azithromycin and dalbavancin and was named Pfizer’s first Vaccine Development Team Leader. In his career, Dr. Jorgensen has developed novel antibiotics with immunomodulatory properties, such as azalides and defensin mimetics, both of which have ocular applications, and most recently, microbiome-related therapies that correct dysbiosis and reinforce barrier immunity. Dr. Jorgensen has successfully ushered products from early clinical development through full regulatory approval, both in the U.S. and abroad, playing a key role in New Drug Applications (NDAs), Biologics License Applications (BLAs) and FDA Advisory Committee Meetings. Prior to joining the Industry, Dr. Jorgensen was an Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control and Prevention (CDC). Dr. Jorgensen received his undergraduate degree from Yale, his MD from the University of Wisconsin, his MPH from the University of Washington, and his MBA from Yale. He is board-certified in pediatrics, infectious diseases, and preventive medicine.
Charlie Kang, MBA
Mr. Kang is the Chief Financial Officer of Ocugen, Inc. Prior to Ocugen, Mr. Kang was with Johnson & Johnson (J&J) where he led business development for the DePuy Synthes Biologics Business Unit, which was responsible for acquiring new technologies through M&A and partnerships. Prior to J&J, Mr. Kang held senior strategy, business development, and corporate development roles at Synthes, Aspen Biopharma, and Life Technologies. Mr. Kang started his biotech career in R&D at Somatogen Inc. a company focused on developing recombinant hemoglobin-based blood substitutes. Mr. Kang obtained his MBA and his Bachelors in Molecular, Cellular, and Developmental Biology from the University of Colorado.
Rasappa Arumugham, PhD
Dr. Arumugham serves as the Vice President of Research and Development at Ocugen, Inc. He has over 30 years of diverse experience in leading biopharmaceutical research and development in the areas of discovery and pre-clinical research, formulation, analytical development, quality control, technology transfer and manufacturing. He has a proven track record in drug development, scale-up, and technology transfer supporting commercialization of vaccines and biologics including Prevnar®, Prevnar®13, TetramuneTM, Meningitec® and Trumenba®.
Dr. Arumugham was the Vice President of Biopharmaceutical Development at Soligenix, Inc where he led the pharmaceutical development and manufacturing of biologics, peptides and small molecules in support of injectable and topical formulations. He also served as the Principal Investigator for the development of a heat-stable ricin vaccine program funded by the US government (NIAID). Previously, he served as the Head of Microbial Analytics at Merck’s Manufacturing Division. Prior to joining Merck, Dr. Arumugham spent 25 years in various biologics/vaccines research and development positions of increasing responsibilities at Pfizer and Wyeth. Dr. Arumugham earned his PhD and MSc in Biochemistry and BSC in Chemistry from the University of Madras, India.
Vijay Tammara, PhD
Dr. Tammara has over 20 years of leadership experience in the field of global regulatory affairs, strategic drug development, clinical strategy, and has made significant contributions to the approval of several products. His regulatory expertise spans both oral and injectable dosage forms of small molecules, peptides, proteins, monoclonal antibodies and vaccines. Dr. Tammara previously served as VP Regulatory Affairs at Nuron Biotech Inc., Director Regulatory Affairs at Merck & Co., Inc., Senior Associate Director at Wyeth Pharmaceuticals, and Assistant Director at Sanofi-Synthelabo in Worldwide Regulatory Affairs. Prior to industrial positions, Dr. Tammara held positions of increasing responsibility in the Office of Clinical Pharmacology and Biopharmaceutics at the FDA and received several FDA awards including the CDER Outstanding Reviewer Award, FDA Outstanding Achievement Award, and Awards of Excellence. Dr. Tammara received his Bachelor of Pharmacy from Kakatiya University, Masters in Pharmacy from Nagpur University, and Ph.D. in Pharmaceutics from the University of Louisiana, Monroe, LA.
Kelly Morello, MBA, SPHR, SHRM-SCP, PMP
Ms. Morello brings significant experience working with start-up organizations and rapid growth companies, with the last 12 years focused in the life sciences industry. In her role at Ocugen, she is responsible for communications, investor relations, human resources, information technology and facilities. Ms. Morello has served in senior human resources leadership roles with PRA Health Sciences, DrugDev (formerly CFS Clinical), Tengion and General Fiber Communications. Ms. Morello obtained her MBA from Penn State, MS in Human Resource Development from Villanova and a BS in Business Administration with a concentration in Accounting from Millersville University. She also holds SPHR, SHRM-SCP and PMP certifications.